FeesSafety
Pluang+

Hansa Biopharma reports strong Q3 revenue growth after €110M SERB licensing deal and starts commercial use in Australia

Company Fundamentals
11 Nov 2026, 08:37 WIB
PRNewsWire
View Source
Bullish
Hansa Biopharma reports strong Q3 revenue growth after €110M SERB licensing deal and starts commercial use in Australia

Hansa Biopharma closed a €110 million licensing deal with SERB Pharmaceuticals, boosting Q3 revenue to 143.0 MSEK from 30.8 MSEK a year earlier. The deal grants SERB exclusive rights to market Idefirix in Europe and MENA, with the European Commission transferring marketing authorization to SERB. The company also began commercial use of Idefirix in Australia with the first kidney transplant patient treated. Despite increased revenue, Hansa reported a loss due to higher expenses but strengthened its cash position to 1,337.2 MSEK. The company is preparing for a potential US launch of imlifidase and advancing clinical programs in Guillain-Barré syndrome.

Hansa Biopharma's Q3 and interim 2026 results provide context for health sector trading. For readers following health stocks, here is Pluang's market snapshot as of Nov 11, 2026 11:02 WIB: Out of 150 priced US health stocks, 48 rose and 100 fell. Notable movers include CRSP at USD 45.86 with a 1-day change of -8.35% and 99% sell order activity, TNGX at USD 24.60 up 8.18% with balanced buy/sell orders, and CTXR at USD 0.49 down 7.51% with 99% buy order activity.

More News

ABN AMRO reports 52% profit rise to €940M in Q3 2026, boosts full-year net interest income forecast.

ABN AMRO reports 52% profit rise to €940M in Q3 2026, boosts full-year net interest income forecast.

ABN AMRO posted a net profit of €940 million in Q3 2026, a 52% increase year-on-year, driven by strong lending, deposits growth, and the acquisition of NIBC. The bank raised its full-year net interest income guidance to over €6.9 billion, supported b...

Company Fundamentals
Bullish
1 hour ago
Artesian Resources misses Q3 earnings and revenue estimates despite 4.8% revenue growth.

Artesian Resources misses Q3 earnings and revenue estimates despite 4.8% revenue growth.

Artesian Resources Corporation reported Q3 2026 earnings of $0.65 per share, missing the $0.67 estimate and down from $0.68 a year earlier. Revenue rose 4.8% year-over-year to $31.9 million but fell short of the $32.2 million forecast. Net income dec...

Company Fundamentals
Bearish
3 hours ago
US coffee market to reach $32.2B by 2032, driven by specialty coffee and premiumization trends.

US coffee market to reach $32.2B by 2032, driven by specialty coffee and premiumization trends.

The US coffee market is projected to grow from $26.1 billion in 2027 to $32.2 billion by 2032, with a CAGR of 4.32%. Specialty coffee is the fastest-growing segment, expanding at 6.78% CAGR due to rising demand for premium and functional coffee optio...

Market News
Bullish
4 hours ago
BAIC FOTON launches supercharging strategy with new electric trucks and global charging network plans

BAIC FOTON launches supercharging strategy with new electric trucks and global charging network plans

BAIC FOTON unveiled a new supercharging strategy in Beijing, introducing the world's first supercharged light truck AUMARK Z and heavy-duty megawatt trucks. The strategy integrates vehicles, charging stations, grids, and cloud platforms to optimize e...

Market News
Bullish
4 hours ago
BAIC FOTON launches supercharging strategy with new electric trucks to boost global smart energy ecosystem.

BAIC FOTON launches supercharging strategy with new electric trucks to boost global smart energy ecosystem.

BAIC FOTON unveiled its Supercharging Strategy in Beijing, introducing the world's first supercharge-capable light-duty AUMARK Z truck and megawatt-class heavy-duty trucks. This integrated energy management system connects vehicles, charging stations...

Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App